Table 2.

Study 2 design and efficacy of oral moxidectin against Dirofilaria immitis (JYD-34, ZoeLA)

Strain	Groupa (n = 5)	Treatmentb	Dosage (µg/kg)	Days of treatment	No. of dogs with worms	Adult D. immitis worm countsc
						Individual worm counts	Geometric meand	% reductione
JYD-34	T01	Placebo	na	0, 28, 56	5 of 5	5, 23, 27, 33, 33	20.6f	–
	T03	Moxidectin	24	0, 28, 56	1 of 5	2	0.2g	98.8
	T04	Moxidectin	40	0, 28, 56	0 of 5	0	0g	100.0
	T05	Moxidectin	60	0, 28, 56	0 of 5	0	0g	100.0
ZoeLA	T02	Placebo	na	0, 28, 56	5 of 5	25, 26, 31, 37, 38	30.9f	–
	T06	Moxidectin	3	0	5 of 5	11, 13, 17, 19, 25	20.0g	44.4
	T07	Moxidectin	24	0, 28, 56	1 of 5	1	0.1h	99.5
	T08	Moxidectin	40	0, 28, 56	1 of 5	1	0.1h	99.5
	T09	Moxidectin	60	0	5 of 5	1, 1, 6, 6, 10	3.6i	88.2
	T10	Moxidectin	60	0, 28, 56	0 of 5	0	0h	100

^aAll dogs were inoculated with 50 D. immitis L3 at Day -30. Groups T01 and T03–T05 received the JYD-34 strain; Groups T02 and T06–T10 received the ZoeLA strain

^bMoxidectin administered as ProHeart^® tablets shaved to deliver the correct dose

^cAll dogs were necropsied for recovery and enumeration of adult heartworms on Day 103 (133 days post-inoculation)

^dMeans with different superscript letters (f–i) are significantly different within each strain t₍₃₄₎ = 2.33, P = 0.0259 for T02 vs T06; 7.36 ≤ t₍₃₄₎ ≤ 13.21, P < 0.0001 for all other significant differences

^ePercentage reduction is compared to T01 for Groups T03–T05 and compared to T02 for Groups T06–T10

Abbreviation: na, not applicable